Castle Biosciences Incorporated announced that it will receive $5,475,746 in funding on January 12, 2018. The company will issue common shares and preferred warrants in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The total amount includes amounts receivable by the company upon exercise of warrants to purchase the preferred shares of the company.